Table 2.
ROS | Source | Cancer type | Molecular target | Reference |
---|---|---|---|---|
Induction of cell death | ||||
In vitro studies | ||||
H2O2 | Exogenous | Lymphoma | Capase-3 ↑a | (114) |
Exogenous | Bladder | MEK1/2 ↑a, ERK1/2 ↑a | (59) | |
Caspase-3 ↑a, Caspase-7 ↑a | ||||
Apigenin | Hepatoma | Catalase ↓ | (310) | |
PDT | Leukemia | Caspase 3 ↑a | (248) | |
Melatonin | Leukemia | Caspase-3 ↑a, Caspase-8 ↑a | (28) | |
Caspase-9 ↑a | ||||
PL | Osteosarcoma, breast, bladder, lung | Bcl-2 ↓, Survivin ↓, XIAP ↓ | (252) | |
NO | PL | Osteosarcoma, Breast, Bladder, Lung | Bcl-2 ↓, Survivin ↓, XIAP ↓ | (252) |
ROS | Bortezomib | Gastric | NF-κB ↓b, JNK ↑a | (228) |
Orthovanadate | Thyroid | mTOR ↑a, PI3K/AKT ↑a, Caspase-3 ↑a | (102) | |
Bufalin | Colon | JNK ↑a, ATG5 ↑, Beclin-1 ↑ | (336) | |
Capsaicin | Colon | Caspase-3 ↑a, Caspase-8 ↑a, | (198) | |
Caspase-9 ↑a, Bax ↑, Bcl-2 ↓ | ||||
Eugenol | Colon | p53 ↑, Caspase-3 ↑ | (142) | |
Cantharidin | Bladder | Caspase-3 ↑a, Caspase-8 ↑a, | (172) | |
Caspase-9 ↑a, Bax ↑, Bcl-2 ↓ | ||||
GA | Bladder | p-p53 ↑ | (188) | |
Cajanol | Breast | Caspase-3 ↑a, Caspase-9 ↑a | (202) | |
Bax ↑, Bcl-2 ↓ | ||||
Ginseng | Breast | COX-2 ↓, PGE-2 ↓ | (155) | |
BITC | Osteosarcoma | Caspase-3 ↑a, Caspase-9 ↑a | (331) | |
PEITC | Osteosarcoma | Caspase-3 ↑a, Caspase-9 ↑a | (331) | |
Selenite | Osteosarcoma | Caspase-3 ↑a, Bcl-2 ↓ | (52) | |
p53 ↑, PTEN ↑ | ||||
ABITC | Endometrial | Caspase-8 ↑a, JNK ↑a, SAPK ↑a | (123) | |
Garcinol | Hepatocellular | Bax ↑, Bcl-2 ↓, Caspase-3 ↑a | (55) | |
Caspase-8 ↑a, Caspase-9 ↑a | ||||
Casticin | Cervical | Caspase-3 ↑a, Caspase-9 ↑a, Bax ↑ | (49) | |
Bcl-xL ↓, XIAP ↓ | ||||
Deltonin | Multiple | Bcl-2 ↓; Bax ↑, Caspase-3 ↑a | (282) | |
Caspase-9 ↑a, AKT ↑a, MAPK ↑a | ||||
Pipoxolan | Leukemia | Bcl-2 ↓, Bcl-xL ↓, MiMP ↓, Bax ↑ | (54) | |
ESB | Leukemia | Caspase-3 ↑a, Caspase-9 ↑a | (6) | |
UDCA | Gastric | DR5 ↑, PKC-δ ↑a, Caspase-3 ↑a | (185) | |
Caspase-6 ↑a, Caspase-8 ↑a | ||||
Carnosic Acid | Neuroblastoma | Bcl-2 ↓, Caspase-3 ↑a, Caspase-9 ↑a | (303) | |
Withaferin A | Melanoma | Bcl-2 ↓, Bax↑, Bim↑, Caspase-3 ↑a | (215) | |
Caspase-9 ↑a | ||||
EGCG | Chondrosarcoma | Bax ↑, Bak ↑, Bcl-2 ↓, Bcl-xL ↓ | (343) | |
Thymoquinone | Lymphoma | Caspase-3 ↑a, Caspase-9 ↑a, DR5 ↑ | (130) | |
Progesterone | Ovarian/Endometrial | p53 ↑, Bax ↑, Bcl-2 ↓ | (231) | |
Danthron | Gastric | Caspase-3 ↑a, Caspase-8 ↑a | (58) | |
Caspase-9 ↑a, Bax ↑, Bcl-2 ↓ | ||||
Tricetin | Liver | DR5 ↑ | (126) | |
In vivo studies | ||||
H2O2 | PL | Breast, Bladder, Lung | Bcl-2 ↓, Survivin ↓, XIAP ↓ | (252) |
NO | PL | Breast | Bcl-2 ↓, Survivin ↓, XIAP ↓ | (252) |
ROS | CHL | Leukemia | Caspase-8 ↑a, Caspase-9 ↑a, MiMP ↓ | (254) |
AGL | Lymphoma | Caspase-3 ↑a, Caspase-8 ↑a | (341) | |
Caspase-9 ↑a | ||||
DMAPT | Prostate | NF-κB ↓, JNK ↑, TRAF2 ↓, | (276) | |
Caspase-8 ↑a, XIAP ↓ | ||||
Inhibition of cell death | ||||
ROS | Endogenous | Prostate | ND | (41) |
IGF-I | Pancreatic | JAK2 ↑a | (178) |
ND, not determined; ↑a, activation; ↓b, inactivation; ↓, down-regulation; ↑, up-regulation.
ABITC, abietyl isothiocyanate; AGL, andrographolide; AKT, AKT8 virus oncogene cellular homolog; ATG5, autophagy protein 5; Bak, Bcl-2 homologous antagonist/killer; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma-2; Bcl-xL, B-cell lymphoma-extra large; Bim, Bcl-2-interacting mediator; BITC, benzyl isothiocyanate; CHL, chlorogenic acid; COX-2, cyclooxygenase-2; DMAPT, dimethylaminoparthenolide; DR5, death receptor 5; EGCG, epigallocatechin gallate; ERK1/2, extracellular signal-regulated kinase 1/2; ESB, erythrina suberosa stem bark; GA, 18 β-glycyrrhetinic acid; H2O2, hydrogen peroxide; IGF-I, insulin-like growth factor-1; JAK2, janus kinase 2; JNK, c-jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK1/2, MAPK/ERK kinase 1/2; MiMP, mitochondrial membrane potential; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NO, nitric oxide; PDT, photodynamic therapy; PEITC, β-phenylethylisothiocyanate; PGE-2, prostaglandin E2; PI3K, phosphoinositide 3-kinase; PKC-δ, protein kinase C-delta; PL, piperlongumine; PTEN, phosphatase and tensin homolog deleted on chromosome 10; SAPK, stress-activated protein kinase; TRAF2, TNF receptor-associated factor 2; UDCA, ursodeoxycholic acid; XIAP, X-linked inhibitor of apoptosis protein.